First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis
Yi, Lidan, Zhou, Zhen, Zeng, Xiaohui, Tan, Chongqing, Liu, Qiao
Published in Frontiers in immunology (05.07.2024)
Published in Frontiers in immunology (05.07.2024)
Get full text
Journal Article
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
Liu, Qiao, Tan, Chongqing, Yi, Lidan, Wan, Xiaomin, Peng, Liubao, Li, Jianhe, Luo, Xia, Zeng, Xiaohui
Published in PloS one (15.11.2021)
Published in PloS one (15.11.2021)
Get full text
Journal Article
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
Wang, Liting, Peng, Ye, Qin, Shuxia, Wan, Xiaomin, Zeng, Xiaohui, Li, Sini, Liu, Qiao, Tan, Chongqing
Published in PloS one (13.04.2023)
Published in PloS one (13.04.2023)
Get full text
Journal Article
Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study
Wu, Meiyu, Qin, Shuxia, Tan, Chongqing, Li, Sini, Xie, Ouyang, Wan, Xiaomin
Published in BMC medicine (27.07.2023)
Published in BMC medicine (27.07.2023)
Get full text
Journal Article
Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma
Zhang, Haixia, Zeng, Xiaohui, Peng, Ye, Tan, Chongqing, Wan, Xiaomin
Published in Frontiers in pharmacology (26.04.2022)
Published in Frontiers in pharmacology (26.04.2022)
Get full text
Journal Article
Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
Zhou, Dongchu, Luo, Xia, Zhou, Zhen, Zeng, Xiaohui, Wan, Xiaomin, Tan, Chongqing, Liu, Qiao
Published in Frontiers in pharmacology (25.08.2022)
Published in Frontiers in pharmacology (25.08.2022)
Get full text
Journal Article
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
Li, Andong, Wu, Meiyu, Xie, Ouyang, Xiang, Heng, Meng, Kehui, Tan, Chongqing, Wang, Long, Wan, Xiaomin
Published in Frontiers in immunology (09.09.2024)
Published in Frontiers in immunology (09.09.2024)
Get full text
Journal Article
Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
Chongqing, Tan, Sini, Li, Xiaohui, Zeng, Liubao, Peng, Ye, Peng, Shuxia, Qin, Liting, Wang, Meiyu, Wu, Xiaomin, Wan
Published in Frontiers in pharmacology (14.12.2021)
Published in Frontiers in pharmacology (14.12.2021)
Get full text
Journal Article
First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
Liu, Qiao, Zhou, Zhen, Luo, Xia, Yi, Lidan, Peng, Liubao, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui
Published in Frontiers in pharmacology (21.12.2021)
Published in Frontiers in pharmacology (21.12.2021)
Get full text
Journal Article
Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
Wu, Meiyu, Qin, Shuxia, Wang, Liting, Tan, Chongqing, Peng, Ye, Zeng, Xiaohui, Luo, Xia, Yi, Lidan, Wan, Xiaomin
Published in Frontiers in pharmacology (14.04.2022)
Published in Frontiers in pharmacology (14.04.2022)
Get full text
Journal Article
Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR
Zeng, Xiaohui, Peng, Liubao, Peng, Ye, Tan, Chongqing, Wan, Xiaomin
Published in Clinical therapeutics (01.02.2020)
Published in Clinical therapeutics (01.02.2020)
Get full text
Journal Article
Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis
Tan, Chongqing, Luo, Xia, Li, Sini, Yi, Lidan, Zeng, Xiaohui, Peng, Liubao, Qin, Shuxia, Wang, Liting, Wan, Xiaomin
Published in Clinical rheumatology (2022)
Published in Clinical rheumatology (2022)
Get full text
Journal Article
Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China
Zeng, Li, Chen, Huihui, Xiang, Heng, Zeng, Mengru, Zhou, Mi, Tan, Chongqing, Liu, Hong, Chen, Guochun
Published in Frontiers in pharmacology (08.01.2024)
Published in Frontiers in pharmacology (08.01.2024)
Get full text
Journal Article
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, Chongqing
Published in BMJ open (26.11.2020)
Published in BMJ open (26.11.2020)
Get full text
Journal Article
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
Wan, Xiaomin, Zeng, Xiaohui, Peng, Liubao, Peng, Ye, Liu, Qiao, Yi, Lidan, Luo, Xia, Deng, Qijian, Tan, Chongqing
Published in Frontiers in pharmacology (23.08.2021)
Published in Frontiers in pharmacology (23.08.2021)
Get full text
Journal Article